Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $438.00 : vimarsana.com

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective hoisted by equities research analysts at JPMorgan Chase & Co. from $390.00 to $438.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price […]

Related Keywords

Brucei Sachs , Robertw Baird , , News Ratings For Vertex Pharmaceuticals Daily , Lindbrook Capital , Vertex Pharmaceuticals , Sumitomo Mitsui Ds Asset Management Company Ltd , Vertex Pharmaceuticals Trading Down , Jpmorgan Chase Co , Analyst Recommendations For Vertex Pharmaceuticals , Vertex Pharmaceuticals Incorporated , Vertex Pharmaceuticals Company Profile , Canaccord Genuity Group , Institutional Trading Of Vertex Pharmaceuticals , Cantor Fitzgerald , Nicholas Hoffman Company , Get Free Report , Genuity Group , Pharmaceuticals Trading Down , Chairman Jeffrey , Director Bruce , Management Company Ltd , Pharmaceuticals Incorporated , Vertex Pharmaceuticals Daily , Nasdaq Vrtx , Vrtx , Medical , 92532f10 , Boost Price Target ,